<DOC>
	<DOCNO>NCT02999633</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy isatuximab . Secondary Objectives : - To evaluate safety profile isatuximab . - To evaluate duration response ( DOR ) . - To evaluate progression free survival ( PFS ) overall survival ( OS ) . - To evaluate pharmacokinetics ( PK ) isatuximab patient T-ALL T-LBL . - To evaluate immunogenicity isatuximab patient T-ALL T-LBL . - To assess minimal residual disease ( MRD ) correlate clinical outcome .</brief_summary>
	<brief_title>Safety Efficacy Isatuximab Lymphoblastic Leukemia</brief_title>
	<detailed_description>The study duration per patient include 3-week screening period , approximately 1 year treatment period disease progression discontinuation reason , follow-up period least 30 day last investigational medicinal product administration .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Inclusion criterion : Patients must know diagnosis ALL T cell origin , include TLBL TALL extramedullary involvement relapse confirm biopsy . Patients must previously treat TALL TLBL relapse refractory recent treatment . Patients first relapse eligible regardless first remission duration . Patients must previously expose nelarabine country drug available ( unless due contraindication use administrative issue ) . No 3 prior salvage therapy . Exclusion criterion : Prior treatment immunotherapy/investigational agent within 3 week , chemotherapy within 2 week study treatment . Must recover acute toxicity first study treatment administration . Prior stem cell transplant within 4 month and/or evidence active systemic Graft versus Host Disease and/or immunosuppressive therapy Graft versus Host Disease within 1 week first study treatment administration . Clinical evidence active central nervous system ( CNS ) leukemia . TALL testicular involvement alone . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>